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We thank Professor Warnakulasuriya for his letter (Warnakulasuriya, 2019) and comments in 
relation to our systematic review of prospective studies assessing the prognostic biomarkers 
of oral leukoplakia (Villa et al., 2019). We agree that identifying prognostic biomarkers for 
oral leukoplakia is an important topic for oral medicine specialists.  Hence our commitment 
to addressing such a diverse and scientifically challenging area as a component of World 
Workshop of Oral Medicine VII.  
We would like to clarify, though, that this first paper in a series of papers on the topic, 
examined prognostic biomarkers for oral leukoplakia in context of biomarker expression in 
human subject samples. Details of the search strategy, including potentially eligible studies, 
search terms, and strategy are detailed in our paper (Villa et al., 2019).  
In relation to the putative biomarkers identified by Professor Warnakulasuriya, we would 
agree that many of these have been highlighted in the literature, some being more prognostic 
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 However, several studies that discuss these biomarkers did not meet the inclusion 
criteria for our systematic review. For example, many studies did not specifically 
detail the oral leukoplakia cases, and this hampered inclusion of many papers and 
potential biomarkers, not only those raised by Professor Warnakulasuriya, but also 
some described by authors of the current systematic review. 
 Additionally, as we reported in point “c)” of paragraph “2.1”, we did not include any 
review papers or those discussing meta-analyses, such as the publication by Alaizari 
et al. (2018). We only considered original studies for inclusion and excluded reviews 
or collective analyses of multiple studies. Detailed information of biomarkers 
identified, including prognostic information (when mentioned in the papers), are 
reported in the Supplementary data.  
A recurrent confounder for development of our manuscript was  imprecise description of the 
anatomical location of the lesions. As an example, several cases of not otherwise specified 
“oropharyngeal leukoplakias” could not be included for our analysis. In addition, many 
studies on putative biomarkers for oral leukoplakia actually describe them in terms of 
presence or absence of oral epithelial dysplasia without clear clinical information to warrant 
inclusion. As shown in Table 1 of our paper (Villa et al., 2019), exclusion category N3 
captured 332 studies out of a total of 418 reports ineligible for inclusion due to lack of 
definitive clinical diagnosis and presentation of dysplasia data only.  
We agree that the definition of oral leukoplakia in some studies may have affected the papers 
selected.  However, this in an inherent limitation with the papers themselves, and the broader 
field of oral medicine, and not restricted to the inclusion criteria of our systemic review. We 
acknowledge that authors of some publications  have included keratotic white lesions as 
potential leukoplakia, which complicates analysis of potential biomarkers for the latter 
condition. This issue is highlighted in a recent study by Villa and colleagues (Villa et 
al.,2019) which touches on the molecular profile of non-dysplastic leukoplakic lesions 
commonly reported histopathologically as benign keratosis in the literature, but identified as 
leukoplakia clinically. Unfortunately, without access to all details of studied cases, it is not 
possible to determine which cases could be validated for inclusion.  
Rationale for study exclusion  was clearly articulated in our paper. Although we agree that a 
table summarizing rationale could have been helpful, the sheer number of studies excluded 
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the excluded studies for clarity (Appendix 1) Finally, we agree with Professor 
Warnakulasuriya that few, if any, of the prognostic biomarkers reported in the literature for 
oral leukoplakia are robust. Although some may hold more promise than others, including 
some omitted from our report, we could only report on those which met the inclusion criteria 
of the current systematic review.  
Addressing the following issues in future studies (as we specified in Section 4.1 “Future 
directions” in the manuscript) would further strengthen the quality and clinical value of this 
line of research: 
 Both clinical and histopathological details should be provided to allow analysis of 
clinical entities such as leukoplakia and corresponding histopathological entities such 
as dysplasia, in terms of identification of putative biomarkers. A recent paper by 
Farah and Fox (Farah and Fox, 2019) discusses this philosophical question by 
identifying the molecular profile of oral leukoplakia with and without dysplasia.  
 A more concerted effort is required internationally to correctly define oral 
leukoplakia, as the current definition is not entirely helpful in a clinical sense.  
 
Respectfully,  
Alessandro Villa, Antonio Celentano, Ingrid Glurich, Wenche S. Borgnakke, Siri Beier 
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